Compare Stocks: CALT, XENE, and VERU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
VERU Veru	$2.52 +3.1%	$2.49	$2.05 ▼ $7.33	$42.88M	-1.17	763,747 shs	73,567 shs
XENE Xenon Pharmaceuticals	$38.79 -0.5%	$61.54	$35.97 ▼ $72.66	$3.75B	0.61	1.32 million shs	1.37 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
VERU Veru	+1.24%	+4.27%	-7.58%	-19.74%	-29.68%
XENE Xenon Pharmaceuticals	-1.91%	-33.00%	-35.84%	-28.60%	+5.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
VERU Veru	$2.52 +3.1%	$2.49	$2.05 ▼ $7.33	$42.88M	-1.17	763,747 shs	73,567 shs
XENE Xenon Pharmaceuticals	$38.79 -0.5%	$61.54	$35.97 ▼ $72.66	$3.75B	0.61	1.32 million shs	1.37 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
VERU Veru	+1.24%	+4.27%	-7.58%	-19.74%	-29.68%
XENE Xenon Pharmaceuticals	-1.91%	-33.00%	-35.84%	-28.60%	+5.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
VERU Veru	2.33	Hold	$24.50	874.16% Upside
XENE Xenon Pharmaceuticals	2.94	Moderate Buy	$70.93	82.89% Upside

Current Analyst Ratings Breakdown

Latest CALT, XENE, and VERU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/18/2026	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$69.00 ➝ $64.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $70.00
9/18/2026	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$71.00 ➝ $55.00
9/18/2026	XENE Xenon Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$97.00 ➝ $90.00
9/18/2026	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$78.00 ➝ $60.00
9/16/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	VERU Veru	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
VERU Veru	N/A	N/A	N/A	N/A	$1.25 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	499.91	N/A	N/A	$7.53 per share	5.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
VERU Veru	-$22.73M	-$0.69	N/A	N/A	N/A	N/A	-47.58%	-35.83%	11/26/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest CALT, XENE, and VERU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/10/2026	Q3 2026	VERU Veru	-$0.32	-$0.30	+$0.02	-$0.30	$1.70 million	N/A
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
VERU Veru	N/A	4.42	4.42
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
VERU Veru	47.16%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
VERU Veru	14.20%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
VERU Veru	230	17.05 million	14.63 million	Optionable
XENE Xenon Pharmaceuticals	370	96.67 million	93.85 million	Optionable

CALT, XENE, and VERU Headlines

Recent News About These Companies

Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

September 22 at 9:00 AM | seekingalpha.com

Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

September 22 at 7:47 AM | globenewswire.com

Xenon stock lost 30%, but the FDA story is more complicated

September 21 at 11:37 PM | msn.com

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 21 at 4:30 PM | financialpost.comF

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 21 at 4:01 PM | globenewswire.com

Xenon shares slide more than 30% as company pauses psychiatry trial enrollment

September 21 at 1:36 PM | thepharmaletter.comT

Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment

September 21 at 1:36 PM | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Sees Unusually-High Trading Volume - Time to Buy?

September 21 at 12:19 PM | marketbeat.com

Xenon Pharmaceuticals Inc (XENE)

September 20 at 2:39 PM | za.investing.com

Robert W. Baird Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

September 20 at 3:22 AM | americanbankingnews.com

Needham & Company LLC Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

September 20 at 3:22 AM | americanbankingnews.com

Royal Bank Of Canada Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $70.00

September 20 at 2:40 AM | americanbankingnews.com

Wedbush Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00

September 20 at 2:02 AM | americanbankingnews.com

Goldman Sachs Sticks to Its Buy Rating for Xenon (XENE)

September 19 at 11:21 PM | theglobeandmail.com

Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data

September 19 at 11:21 PM | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded to "Strong Sell" Rating by Wall Street Zen

September 19 at 1:11 AM | marketbeat.com

Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade)

September 18, 2026 | seekingalpha.com

XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial

September 18, 2026 | finance.yahoo.com

Xenon Pharmaceuticals falls 30% after depression trial enrollment pause

September 18, 2026 | proactiveinvestors.com

Xenon Pharma Tumbles On Azetukalner Psychiatry Trial Enrollment Pause; Files Focal Seizure NDA

September 18, 2026 | rttnews.com

Is Xenon Pharmaceuticals (XENE) Stock a Buy After Its Worst Drop in Nearly a Decade?

September 18, 2026 | coincentral.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, XENE, and VERU Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 09/21/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Veru NASDAQ:VERU

$2.52 +0.08 (+3.07%)

As of 02:57 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Xenon Pharmaceuticals NASDAQ:XENE

$38.78 -0.21 (-0.53%)

As of 02:58 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALT, XENE, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALT, XENE, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALT, XENE, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, XENE, and VERU Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Veru NASDAQ:VERU

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CALT, XENE, and VERU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CALT, XENE, and VERU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CALT, XENE, and VERU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT, XENE, and VERU Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Veru NASDAQ:VERU

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools